Acute cholestatic hepatitis induced by Epstein–Barr virus infection in an adult: a case report by Anthony Khoo
CASE REPORT Open Access
Acute cholestatic hepatitis induced by




Background: Acute cholestatic hepatitis without features of infectious mononucleosis is a rare presentation of
primary Epstein–Barr infection, with only several cases previously reported in the medical literature. Early
investigation for Epstein–Barr virus in febrile patients with deranged liver function tests and no demonstrable biliary
obstruction on imaging can expedite both diagnosis and treatment, thereby avoiding costly or invasive procedures
such as liver biopsy.
Case presentation: A 59-year-old white woman of Anglo-Saxon descent presenting with a febrile illness was noted
to have a cholestatic picture of deranged liver function tests. Over the following week a progressive obstructive
jaundice developed, with no evidence of choledocholithiasis on ultrasound or magnetic resonance
cholangiopancreatography. Specific immunoglobulin M antibodies against Epstein–Barr virus were detected in her
serum and the diagnosis of Epstein–Barr hepatitis was confirmed by polymerase chain reaction testing. Supportive
treatment was implemented and her liver function had normalized 3 months after presentation.
Conclusions: Epstein–Barr virus is associated with a wide variety of clinical manifestations and can present as
cholestatic hepatitis with or without features of infectious mononucleosis. While the diagnosis is often suggested
by serological testing, Epstein–Barr virus polymerase chain reaction is a new non-invasive laboratory study that can
help identify infection in cases where the clinical presentation is atypical.
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Background
Epstein–Barr virus (EBV) is a ubiquitous human herpes-
virus with a worldwide prevalence in the adult popula-
tion that approaches 90 %, the majority of infections
being both subclinical and inapparent. Transient in-
creases in hepatic transaminases during primary infec-
tion are not uncommon but significant icterus and
cholestasis are rare, with an incidence of less than 5 %
[1]. Only several cases of EBV-induced cholestasis with-
out features of infectious mononucleosis such as pharyn-
gitis and glandular swelling have been previously
reported in the medical literature [2].
Primary EBV infection can be identified by the pres-
ence of immunoglobulin M (IgM) antibodies directed
against the Epstein–Barr viral capsid antigen (VCA).
Anti-VCA immunoglobulin G (IgG) is produced concur-
rently early in infection (day 4 to 7) and persists for the
lifetime of an immunocompetent person [3, 4].
EBV polymerase chain reaction (PCR) is a new non-
invasive test which can assist in diagnosing primary in-
fection, particularly when the presentation is atypical.
Furthermore, PCR is more sensitive than antibody test-
ing in early stages of EBV infection [5]. It should be
noted, however, that although it has diagnostic value,
the quantitative aspect of EBV-PCR in immunocom-
petent individuals remains uncertain and the role of
monitoring viral load to measure progression is yet to
be validated [4].
Case presentation
A 59-year-old, previously well, white woman of Anglo-
Saxon descent was admitted to our hospital with a 4-day
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history of intermittent fevers, rigors and chills. She de-
nied pain, shortness of breath, cough or urinary symp-
toms. There was no history of illicit drug use, recent
travel or infective contacts. Her past medical history in-
cluded a previous cholecystectomy and anxiety for which
she was medicated with 200 mg desvenlafaxine.
On presentation, she was febrile at 39.2 °C, had a pulse
rate of 80 beats/minute, blood pressure of 130/64
mmHg, respiratory rate of 14 breaths/minute and oxy-
gen saturations of 99 % on room air. There was no vis-
ible rash, lymphadenopathy or evidence of pharyngitis.
Her cardiovascular, respiratory and abdominal examina-
tions were unremarkable.
Although her initial full blood count indices were
within normal limits, biochemistry revealed a mixed pic-
ture of deranged liver function tests (LFTs) as shown in
Table 1.
A repeat examination the following day revealed
marked icterus in addition to generalized abdominal dis-
comfort and myalgia, with biochemistry showing pro-
gressively worsening cholestatic LFTs and conjugated
hyperbilirubinemia, peaking on the seventh day of ad-
mission (see Table 2).
Her albumin was 25 g/L (34–48) and coagulation stud-
ies were within normal limits. Full blood count and
blood film demonstrated a reactive lymphocytosis:
7.34×109/L; reference range (RR) 1.5–3.5×109/L.
Viral studies revealed a positive EBV IgM and IgG anti-
body. No hepatitis A IgM antibodies were detected. Hepa-
titis B and C serology was negative. Smooth muscle and
mitochondrial antibodies were not detected. An abdominal
ultrasound revealed no evidence of intra- or extrahepatic
duct dilatation or choledocholithiasis. Magnetic resonance
cholangiopancreatography (MRCP) demonstrated an en-
larged spleen at 16 cm but was otherwise unremarkable.
EBV-PCR was performed detecting 68,300 copies of EBV-
ribonucleic acid (RNA) and a diagnosis of acute cholestatic
hepatitis secondary to Epstein–Barr infection was subse-
quently made.
She was managed supportively, with paracetamol 1 g
four times daily to help control pyrexia and a short
course of cholestyramine 4 g three times daily to assist
in managing intractable pruritus. Her clinical condition
gradually improved and on review 3 months after initial
admission her LFTs had returned to within normal
limits.
Discussion
Investigation of an obstructive pattern of LFTs rests
heavily on imaging, as intra- and extrahepatic cholestasis
cannot reliably be differentiated on the basis of
biochemical results alone. Ultrasonography is a cost-
effective, minimally invasive technique which can dem-
onstrate gallstone disease and suggest extrahepatic
cholestasis by revealing biliary dilation, while MRCP is a
more powerful tool reserved for cases in which ultra-
sound imaging is inconclusive.
Once biliary obstruction has been excluded, intrahepa-
tic causes of cholestasis should be investigated. Common
hepatocellular diseases characterized by hyperbilirubine-
mia and a cholestatic picture of LFTs include viral infec-
tions and drugs such as phenytoin or amiodarone.
Primary biliary cirrhosis and cholestasis of pregnancy
are less common causes which can be readily excluded
while infiltrative disorders such as sarcoid, lymphoma
and amyloidosis are rare.
In addition to EBV, other viral causes of intrahepatic
cholestasis include cytomegalovirus and viral hepatitis
A, B, C and E. Acquired immune deficiency syndrome
(AIDS) cholangiopathy is a syndrome of biliary obstruc-
tion resulting from infection-associated stricturing of the
biliary tree, usually seen in patients with a CD4 count
below 100/mm3.
While the pathogenesis of cholestasis in EBV infection
has not been well defined, it is thought to be primarily
an immune-mediated rather than cytotoxic phenomenon
[5]. Proposed mechanisms of cholestatic hepatitis in
EBV include inflammation and swelling of the bile duct
or direct damage to hepatic cells by autoantibody-
mediated activation of free radicals [5–7].
The management of EBV cholestasis is focused on
supportive measures and there is limited data supporting
the use of corticosteroids or antivirals in severe EBV in-
fections [8]. Symptomatic measures can include the use
of simple analgesics and paracetamol to lower fever or a
trial of cholestyramine in cases of intractable pruritus.
Table 1 Initial liver function tests
Test Results Units Reference range
Bilirubin 37 umol/L 6–24
GGT 466 U/L 0–60
ALP 342 U/L 30–110
ALT 728 U/L 0–55
AST 460 U/L 0–45
ALP alkaline phosphatase, ALT alanine transaminase, AST aspartate
aminotransferase, GGT gamma-glutamyl transpeptidase
Table 2 Liver function tests after one week
Test Results Units Reference range
Bilirubin 155 umol/L 6–24
GGT 536 U/L 0–60
ALP 775 U/L 30–110
ALT 364 U/L 0–55
AST 275 U/L 0–45
ALP alkaline phosphatase, ALT alanine transaminase, AST aspartate
aminotransferase, GGT gamma-glutamyl transpeptidase
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Keeping EBV hepatitis in the differential for febrile pa-
tients with a cholestatic picture of LFT derangement can
not only expedite accurate diagnosis and treatment but
may also potentially avoid further costly or invasive diag-
nostic procedures such as liver biopsy and endoscopic
retrograde cholangiopancreatography.
Conclusions
Epstein–Barr-induced cholestatic hepatitis is an import-
ant diagnosis to consider in the patient presenting with
fever and deranged LFTs, particularly when no demon-
strable cholelithiasis is present on imaging. While diag-
nosis can usually be obtained through serological
testing, EBV-PCR is a new technique with high sensitiv-
ity and specificity that can confirm Epstein–Barr infec-
tion in cases where clinical presentation is atypical or
serology inconclusive.
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